Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials

Martin R Gaudinski*, Katherine V Houser*, Kaitlyn M Morabito, Zonghui Hu, Galina Yamshchikov, Ro Shauna Rothwell, Nina Berkowitz, Floreliz Mendoza, Jamie G Saunders, Laura Novik, Cynthia S Hendel, LaSonji A Holman, Ingelise J Gordon, Josephine H Cox, Srilatha Edupuganti, Monica A McArthur, Nadine G Rouphael, Kirsten E Lyke, Ginny E Cummings, Sandra Sitar, Robert T Baier, Bryant M Foreman, Katherine Burgomaster, Rebecca S Pelc, David N Gordon, Christina R DeMaso, Kimberly A Dowd, Carolyn Laurencot, Richard M Schwartz, John R Mascola, Barney S Graham, Theodore C Pierson, Julie E Ledgerwood, Grace L Chen, and the VRC 319 and VRC 320 study teams

Summary

Background The Zika virus epidemic and associated congenital infections have prompted rapid vaccine development. We assessed two new DNA vaccines expressing premembrane and envelope Zika virus structural proteins.

Methods We did two phase 1, randomised, open-label trials involving healthy adult volunteers. The VRC 319 trial, done in three centres, assessed plasmid VRC5288 (Zika virus and Japanese encephalitis virus chimera), and the VRC 320, done in one centre, assessed plasmid VRC5283 (wild-type Zika virus). Eligible participants were aged 18–35 years in VRC19 and 18–50 years in VRC 320. Participants were randomly assigned 1:1 by a computer-generated randomisation schedule prepared by the study statistician. All participants received intramuscular injection of 4 μg vaccine. In VRC 319 participants were assigned to receive vaccinations via needle and syringe at 0 and 8 weeks, 0 and 12 weeks, 0, 4, and 8 weeks, or 0, 4, and 20 weeks. In VRC 320 participants were assigned to receive vaccinations at 0, 4, and 8 weeks and 8 weeks via single-dose needle and syringe injection in one deltoid or split-dose needle and syringe or needle-free injection with the Stratis device (Pharmajet, Golden, CO, USA) in each deltoid. Both trials followed up volunteers for 24 months for the primary endpoint of safety, assessed as local and systemic reactogenicity in the 7 days after each vaccination and all adverse events in the 28 days after each vaccination. The secondary endpoint in both trials was immunogenicity 4 weeks after last vaccination. These trials are registered with ClinicalTrials.gov, numbers NCT02840487 and NCT02996461.

Findings VRC 319 enrolled 80 participants (20 in each group), and VRC 320 enrolled 45 participants (15 in each group). One participant in VRC 319 and two in VRC 320 withdrew after one dose of vaccine, but were included in the safety analyses. Both vaccines were safe and well tolerated. All local and systemic symptoms were mild to moderate. In both studies, pain and tenderness at the injection site was the most frequent local symptoms (37 [46%] of 80 participants in VRC 319 and 36 [80%] of 45 in VRC 320) and malaise and headache were the most frequent systemic symptoms (22 [27%] and 18 [22%], respectively, in VRC 319 and 17 [38%] and 15 [33%], respectively, in VRC 320). For VRC5283, 14 of 14 (100%) participants who received split-dose vaccinations by needle-free injection had detectable positive antibody responses, and the geometric mean titre of 304 was the highest across all groups in both trials.

Interpretation VRC5283 was well tolerated and has advanced to phase 2 efficacy testing.

Introduction

Zika virus is the latest arboviral infection to cause epidemic disease in the western hemisphere.¹ That this flavivirus can infect human beings has been known for 70 years,² but it was not judged to be a public health threat until outbreaks occurred in Yap Island in 2006,³ French Polynesia in 2013,⁴ and the Americas and southeast Asia in 2015.⁵ Zika virus infection causes clinical symptoms in about 20% of individuals, of which macular or papular rash, fever, arthritis, arthralgia, non-purulent conjunctivitis, myalgia, headache, retro-orbital pain, oedema, and vomiting are most frequent.⁶ Aeles spp mosquitoes are the main sources of infection, but sexual⁷ and other forms of transmission are possible and can lead to spread to non-endemic regions.⁸ Over 700,000 cases of autochthonous Zika virus infection have been reported in the Americas since 2015,⁹ and have revealed previously unrecognised sequelae. In December, 2015, the Pan American Health Organization and WHO issued an alert linking Zika virus infection with Guillain-Barré syndrome and congenital malformations, including microcephaly. WHO later declared Zika virus to be a Public Health Emergency of International Concern.¹⁰ The causal links between Zika virus infection with these syndromes are supported,¹¹ but the mechanism of infection-related microcephaly is unknown and its epidemiology is complex.¹² As no effective treatments are
yet available and infection is often subclinical, development of a preventive vaccine is urgently needed.

DNA vaccines are safe and immunogenic for many pathogens, including flaviviruses, although none has been licensed for use in human beings.11–12 A DNA vaccine consists of a plasmid containing coding DNA sequences for virus-specific antigens, a promoter region that enables transcription, and a polyadenylation sequence that facilitates protein translation. Importantly, once a manufacturing process and the safety and immunogenicity of the plasmid have been established, the coding sequences can be changed to those for other known antigens to accelerate identification of novel candidate vaccines, and in some cases reduce the regulatory requirements with minimal preclinical toxicity data. The established manufacturing technologies, previous data on toxicity and safety, inherent DNA stability, and ability to elicit antibody and CD8 T-cell responses make DNA vaccines an attractive option for rapidly responding to emerging infectious diseases.

The Vaccine Research Center (VRC) of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA, has experience developing DNA vaccines against viruses including HIV, Ebola virus, severe acute respiratory syndrome coronavirus, influenza virus, and West Nile virus.13,14,16,17,19 The VRC used this experience to develop two DNA vaccine candidates, VRC5288 and VRC5283, against Zika virus. We used West Nile virus vaccines as templates because of the expected biological similarity between members of the Flavivirus genus, and because they have been safe and have induced substantial and durable neutralising activity in clinical trials.20 Into the plasmid backbone, we inserted sequences from Zika virus prM and E genes, which encode protein prM (prM) and envelope protein E (E), respectively. When these proteins are expressed in mammalian cells, they assemble into subviral particles that are non-infectious but have structural and antigenic similarities to virion particles and can induce protective immune responses.20,21 Because preclinical studies were being done in parallel with manufacturing, initial product choice was based on in-vitro data and the final choice was based on animal model data. Therefore, we assessed two DNA vaccine candidates that expressed different prM and E antigen designs because we were uncertain that preclinical
Articles

expression and immunogenicity data would predict clinical outcomes.

VRC5288 and VRC5283 are similar, but VRC5288 has an E region that contains both Zika virus and Japanese encephalitis virus sequences, whereas VRC5283 has an E region that contains wild-type Zika virus sequences. The E protein produced by VRC5288 is chimeric, with the extracellular region being of Zika virus origin and the stem and transmembrane regions being made up of 98 aminoacids from the Japanese encephalitis virus. This Japanese encephalitis virus sequence was used because it improved the release of subviral particles in non-human primates, which was thought to have potential for improving immunogenicity, but, without surface exposure on mature particles, were not expected to contribute otherwise to the induction of protective immunity to Japanese encephalitis virus.22

In non-human primates, the two Zika virus vaccine candidates induced robust neutralising antibody responses after two doses given 4 weeks apart. 17 of 18 animals who received two 4 mg doses of VRC5288 or two 4 mg or 1 mg doses of VRC5283 were protected from viraemia following Zika virus challenge 8 weeks after vaccination.22 The animal that broke through received two 4 mg doses of VRC5288. Based on these findings, both vaccines were advanced into phase 1 clinical trials to assess safety, tolerability, and immunogenicity in human beings before advancing into phase 1 clinical trials to assess safety, tolerability, and immunogenicity in human beings before

Methods

Study design and participants

VRC 319 and VRC 320 are phase 1, randomised, open-label clinical trials of Zika virus DNA vaccine candidates. Eligible participants were healthy adults, aged 18–35 years in VRC 319 and 18–50 years in VRC 320, without abnormal findings in clinical laboratory tests, medical history, or physical examinations. Volunteers for VRC 319 were recruited at the NIH Clinical Center, Bethesda, MD, and the University of Maryland Center for Vaccine Development, Baltimore, MD, USA, and the Hope Clinic of the Emory Vaccine Center, Decatur, GA, USA, and those for VRC 320 were recruited at the NIH Clinical Center.

The NIAID institutional review board reviewed and approved the protocols, and provided oversight for both studies. Reliance agreements with the University of Maryland and Emory Federalwide Assurance were in place for VRC 319. We followed the Department of Health and Human Services guidelines for the protection of human beings in research, and all participants provided written informed consent before enrolment.

Randomisation and masking

In both trials, we used computer-generated randomisation schedules prepared in advance by the study statistician to assign participants to vaccination groups. The schedules were provided to the study site pharmacies and the data management centre. Research nurses enrolled participants. In VRC 319 participants were assigned 1:1 to four different vaccination schedules. In VRC 320 participants were assigned 1:1 to three groups of single-dose or split-dose vaccination.

Vaccines

The vaccines consist of phosphate buffered saline, purified plasmid comprising mammalian expression control elements, coding sequences for Zika virus prM and E from a French Polynesia isolate (strain H/PF/2013), and standard bacterial origin of replication and selection elements. In the VRC5288 vaccine, the Zika virus coding sequence was modified by substituting Japanese encephalitis virus sequences for the stem and transmembrane regions of the E protein, and in both vaccines, the prM signal sequence in the Zika virus coding sequence was exchanged with an analogous Japanese encephalitis virus region to improve secretion of Zika subviral particles from transfected cells. Both vaccines were manufactured by the VRC Pilot Plant, operated under contract by Leidos Biomedical Research (Frederick, MD, USA) according to Good Manufacturing Practices, and supplied in doses of 4 mg/mL.

Study procedures

4 mg vaccine was given in all vaccinations. Volunteers enrolled into VRC 319 received VRC5288 at single intramuscular injections given via needle and syringe. Group 1 received vaccine on weeks 0 and 8, group 2 on weeks 0 and 12, group 3 on weeks 0, 4, and 8, and group 4 on weeks 0, 4, and 20. VRC 319 was originally designed to assess VRC5288 delivered by the needle-free Stratis device (Pharmajet, Golden, CO, USA), but a modification was needed to deliver a DNA vaccine with high viscosity that was not made in time for the trial. The device, therefore, was only used in the VRC 320 trial. Volunteers enrolled into VRC 320 received VRC5283 on weeks 0, 4, and 8. Group 1 received single doses given via needle and syringe into one deltoid; group 2 received split doses (2 mg each), one in each deltoid, given via needle and syringe; and group 3 received split doses (2 mg each), one into each deltoid, given via syringe and needle-free device, in which a spring-powered injector pressurises a narrow stream of vaccine into the tissue without electro-poration or other externally applied factors.

Outcomes

The primary endpoint was vaccine safety, assessed by local and systemic reactogenicity. Safety and tolerability were monitored by clinical and laboratory assessments. Participants used diary cards to record local and systemic reactogenic events occurring in the 7 days after each injection. All adverse events occurring within 28 days after each injection were recorded by clinic staff. Serious adverse events were recorded for the entire duration of the study. These were classified as events or suspected
adverse reactions that, in the view of the investigator or study sponsor, led to death, a life-threatening event, admission to hospital or prolongation of a hospital stay, inability to continue normal life functions, or a congenital anomaly or birth defect, or led to a medical or surgical intervention to prevent one of these outcomes. We used the FDA toxicity grading scale for healthy adults and adolescent volunteers enrolled in preventive vaccine clinical trials. Secondary endpoints were immunogenicity assessed by a reporter virus particle neutralisation assay and antigen-specific T-cell response.

Neutralising antibody responses
Vaccine antibody response was assessed by measuring Zika-virus-specific neutralising antibodies with a previously described reporter virus particle assay. Briefly, Zika virus reporter virus particles were produced in human embryonic kidney 293 T cells by co-transfection with two plasmids, one encoding a green fluorescent protein expression West Nile virus replicon and the other encoding the structural proteins of the flavivirus of heat-inactivated sera in duplicate technical replicates. Zika virus reporter virus particles were incubated with serial threefold dilutions of Zika virus H/PF/2013 strain. Zika virus reporter virus and the other encoding the structural proteins of the fluorescent protein expression West Nile virus replicon transfection with two plasmids, one encoding a green fluorescent protein were counted 24 h after infection by flow cytometry. The dilution of sera needed to neutralise half of infection events (EC50) was estimated by non-linear regression with GraphPad Prism version 7.

Positive antibody response was defined as an EC50 greater than or equal to 30.

T-cell response by intracellular cytokine staining
We used intracellular cytokine staining to assess T-cell responses, as previously described. Briefly, cryopreserved peripheral-blood mononuclear cells were stimulated with overlapping peptide pools (length 15 aminoacids, overlapping by 11 aminoacids) for the Zika virus E protein, small envelope M and peptide pr. Peripheral-blood mononuclear cells were collected at baseline, at the time of each vaccination, and 4 weeks after each vaccination. Data were analysed with FlowJo software (version 9.9.6, Treestar, Ashland, OR, USA). The proportions of total CD4 and CD8 T cells producing interleukin 2, interferon γ, tumour necrosis factor α, or a combination of these cytokines, were quantified. Boolean gating was done and all cytokine-positive gates were summed to calculate the total proportion of cytokine-positive cells responding to a peptide pool. For total vaccine responses, the proportions of cytokine-positive T cells responding to pooled peptides were summed. Groups were analysed with background-subtracted data for positive change from baseline.

Statistical analysis
We calculated sample size primarily on ability to identify serious adverse events. For VRC 319 we estimated that 20 participants per group would provide 90% power to detect at least one serious adverse event within a group if the true rate was not less than 0·142. For VRC 320 we estimated that 15 participants per group would provide 90% power to detect at least one serious adverse event within a group if the true rate was not less than 0·142.
We calculated group-wise magnitudes of antibody response as geometric mean titres (GMTs) with 95% CIs. We used a two-sample *t* test to compare group GMTs within and across trials. We compared magnitude of mean T-cell responses before and after vaccination by Wilcoxon’s signed-rank test within groups and by Wilcoxon’s rank sum test between groups. In accordance with the trial protocols, we made no adjustments for multiple comparisons in the analyses of immunogenicity because the trials were not powered to detect differences.

We did all statistical analyses with R version 3.4.1. These trials are registered with ClinicalTrials.gov, numbers NCT02840487 and NCT02996461.

**Role of the funding source**

The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had access to all the data in the studies and final responsibility for the decision to submit for publication.

**Results**

We enrolled 80 participants of 154 screened in VRC 319, from Aug 2, 2016, to Sept 29, 2016, and 45 of 105 in VRC 320, from Dec 12, 2016, to April 19, 2017 (figure 1). One participant from VRC 319 and two from VRC 320 withdrew after one dose of vaccine due to time commitments, precluding further trial participation, but were included in the safety analyses. Follow-up continues, and is expected to close in August, 2018, for VRC 319 and in February, 2019, for VRC 320. In VRC 319, the groups varied by sex and race, but age, body-mass index, and ethnicity were similar, whereas in VRC 320, only race varied notably (table 1).

Vaccinations were safe and well tolerated in both trials, with local and systemic reactogenic events for VRC5288 and VRC5283 being mild to moderate (appendix). In both studies, pain and tenderness at the injection site was the most frequent local event (37 [46%] of 80 participants in VRC 319 and 36 [80%] of 45 in VRC 320) and malaise and headache were the most frequent systemic events (22 [27%] and 18 [22%], respectively, in VRC 319 and 17 [22%] and 15 [33%], respectively, in VRC 320; table 2). One serious adverse event was reported, which was appendicitis 8 months after vaccination with VRC5288, but was deemed not to be related to vaccination.

The GMTs after vaccination with VRC5288 in VRC 319 were greater after three doses of vaccine than after two doses (table 3, appendix). Positive antibody responses ranged from 60% to 89% 4 weeks after final vaccination (figure 2). The highest GMT and the greatest antibody response and antibody titres were seen in group 4 participants after three doses of vaccine with an extended time between the second and third doses (table 3). After the third dose, the GMT was boosted to greater than the GMTs after the second dose in both three-dose groups (*p*=0·0048 for group 3 and *p*<0·0001 for group 4, figure 3).

The GMTs after vaccination with VRC5288 in VRC 319 were greater after three doses of vaccine than after two doses (table 3, appendix). Positive antibody responses ranged from 60% to 89% 4 weeks after final vaccination (figure 2). The highest GMT and the greatest antibody response and antibody titres were seen in group 4 participants after three doses of vaccine with an extended time between the second and third doses (table 3). After the third dose, the GMT was boosted to greater than the GMTs after the second dose in both three-dose groups (*p*=0·0048 for group 3 and *p*<0·0001 for group 4, figure 3).

The GMT achieved with VRC5283 in VRC 320 was substantially higher with needle-free injection in group 3 than with needle and syringe administration in groups 1 and 2 (table 3). Positive antibody response increased from single-dose needle and syringe administration (77%) to split-dose needle and syringe administration (93%) to split-dose needle-free syringe administration (100%; figure 2). The GMT of 304 in VRC 320 group 3 was the greatest across all groups in both studies (*p*<0·0001 vs groups 1–3 and *p*=0·0028 vs group 4 in VRC 319; *p*=0·0015 vs group 4 in VRC 320).

### Table 1: Baseline characteristics of participants

| VRC 319 trial | VRC 320 trial |
|---------------|---------------|
|               | Group 1 (n=20) | Group 2 (n=20) | Group 3 (n=20) | Group 4 (n=20) | Group 1 (n=15) | Group 2 (n=15) | Group 3 (n=15) |
| **Men**       |               |               |               |               |               |               |               |
|               | 6 (30%)       | 9 (45%)       | 14 (70%)      | 8 (40%)       | 6 (40%)       | 6 (40%)       | 8 (53%)       |
| **Women**     |               |               |               |               |               |               |               |
|               | 14 (70%)      | 11 (55%)      | 6 (30%)       | 12 (60%)      | 9 (60%)       | 9 (60%)       | 7 (47%)       |
| **Age (years)** |               |               |               |               |               |               |               |
| Mean (SD)     | 26.8 (3.0)    | 28.6 (3.5)    | 27.9 (4.5)    | 28.4 (4.0)    | 30.7 (3.3)    | 30.5 (8.1)    | 32.3 (9.8)    |
| Range         | 20–34         | 23–35         | 22–35         | 23–35         | 20–47         | 22–50         | 21–50         |
| **Race**      |               |               |               |               |               |               |               |
| Asian         | 4 (20%)       | 0             | 2 (10%)       | 1 (5%)        | 6 (40%)       | 1 (7%)        | 1 (7%)        |
| Black or African American | 2 (10%) | 6 (30%) | 3 (15%) | 2 (10%) | 1 (7%) | 1 (7%) | 3 (20%) |
| White         | 14 (70%)      | 14 (70%)      | 13 (65%)      | 14 (70%)      | 8 (53%)       | 12 (80%)      | 9 (60%)       |
| Multiracial   | 0             | 2 (10%)       | 3 (15%)       | 0             | 1 (7%)        | 2 (13%)       |               |
| **Ethnicity** |               |               |               |               |               |               |               |
| Non-Hispanic Latino | 20 (100%) | 20 (100%) | 20 (100%) | 19 (95%) | 14 (93%) | 11 (73%) | 14 (93%) |
| Hispanic Latino | 0             | 0             | 0             | 1 (5%)        | 1 (7%)        | 4 (27%)       | 1 (7%)        |
| **Body-mass index (kg/m²)** |               |               |               |               |               |               |               |
| Mean (SD)     | 25.8 (5.4)    | 27.6 (5.7)    | 26.4 (4.1)    | 25.3 (5.9)    | 26.7 (3.0)    | 24.5 (4.2)    | 25.2 (3.5)    |
| Range         | 18.9–39.6     | 20.7–39.2     | 21.3–35.7     | 19.2–35.1     | 21.6–32.3     | 18.7–34.8     | 19.8–31.8     |

See Online for appendix
|                | VRC5288       | VRC5283       |
|----------------|---------------|---------------|
|                | Group 1 (n=20) | Group 2 (n=20) | Group 3 (n=20) | Group 4 (n=20) | Overall (n=80) |
|                | Group 1 (n=15) | Group 2 (n=15) | Group 3 (n=15) | Overall (n=45) |
| **Local symptoms** |               |               |               |               |                |
| **Pain/tenderness** |               |               |               |               |                |
| None           | 9 (45%)       | 11 (55%)      | 10 (50%)      | 13 (65%)      | 43 (54%)       |
| Mild           | 11 (55%)      | 9 (45%)       | 10 (50%)      | 7 (35%)       | 37 (46%)       |
| Moderate       | 0             | 0             | 0             | 0             | 0              |
| **Swelling**   |               |               |               |               |                |
| None           | 19 (95%)      | 20 (100%)     | 20 (100%)     | 20 (100%)     | 79 (99%)       |
| Mild           | 1 (5%)        | 0             | 0             | 0             | 1 (1%)         |
| **Redness**    |               |               |               |               |                |
| None           | 19 (95%)      | 20 (100%)     | 20 (100%)     | 16 (80%)      | 75 (94%)       |
| Mild           | 1 (5%)        | 0             | 0             | 4 (20%)       | 5 (6%)         |
| **Any**        |               |               |               |               |                |
| None           | 9 (45%)       | 11 (55%)      | 10 (50%)      | 11 (55%)      | 41 (51%)       |
| Mild           | 11 (55%)      | 9 (45%)       | 10 (50%)      | 9 (45%)       | 3 (49%)        |
| **Systemic symptoms** |         |               |               |               |                |
| **Malaise**    |               |               |               |               |                |
| None           | 15 (75%)      | 14 (70%)      | 15 (75%)      | 14 (70%)      | 58 (73%)       |
| Mild           | 4 (20%)       | 5 (25%)       | 5 (25%)       | 6 (30%)       | 20 (25%)       |
| Moderate       | 1 (5%)        | 1 (5%)        | 0             | 0             | 2 (3%)         |
| **Myalgia**    |               |               |               |               |                |
| None           | 17 (85%)      | 16 (80%)      | 16 (80%)      | 14 (70%)      | 63 (79%)       |
| Mild           | 2 (10%)       | 3 (15%)       | 4 (20%)       | 5 (25%)       | 14 (18%)       |
| Moderate       | 1 (5%)        | 1 (5%)        | 0             | 1 (5%)        | 3 (4%)         |
| **Headache**   |               |               |               |               |                |
| None           | 16 (80%)      | 16 (80%)      | 16 (80%)      | 14 (70%)      | 62 (78%)       |
| Mild           | 4 (20%)       | 2 (10%)       | 4 (20%)       | 5 (25%)       | 15 (19%)       |
| Moderate       | 0             | 2 (10%)       | 0             | 1 (5%)        | 3 (4%)         |
| **Chills**     |               |               |               |               |                |
| None           | 20 (100%)     | 18 (90%)      | 19 (95%)      | 17 (85%)      | 74 (93%)       |
| Mild           | 0             | 1 (5%)        | 1 (5%)        | 3 (15%)       | 5 (6%)         |
| Moderate       | 0             | 1 (5%)        | 0             | 1 (5%)        | 1 (1%)         |
| **Nausea**     |               |               |               |               |                |
| None           | 19 (95%)      | 18 (90%)      | 20 (100%)     | 16 (80%)      | 73 (91%)       |
| Mild           | 1 (5%)        | 1 (5%)        | 0             | 4 (20%)       | 6 (8%)         |
| Moderate       | 0             | 1 (5%)        | 0             | 0             | 1 (1%)         |
| **Joint pain** |               |               |               |               |                |
| None           | 19 (95%)      | 20 (100%)     | 20 (100%)     | 17 (85%)      | 76 (95%)       |
| Mild           | 1 (5%)        | 0             | 0             | 3 (15%)       | 4 (5%)         |
| Moderate       | 0             | 0             | 0             | 0             | 1 (1%)         |
| **Temperature**|               |               |               |               |                |
| None           | 20 (100%)     | 20 (100%)     | 20 (100%)     | 20 (100%)     | 80 (100%)      |
| Mild           | 12 (65%)      | 12 (65%)      | 10 (50%)      | 12 (60%)      | 48 (60%)       |
| Moderate       | 6 (30%)       | 5 (25%)       | 10 (50%)      | 7 (35%)       | 28 (35%)       |

VRC5288=VRC5288 plasmid backbone with Zika virus and Japanese encephalitis virus envelope protein E. VRC5283=VRC5283 plasmid backbone with wild-type Zika virus envelope protein E.

Table 2: Local and systemic reactogenicity
| GMT (95% CI) | Mean change in CD4 response from baseline (95% CI) | Mean change in CD8 response from baseline (95% CI) |
|-------------|---------------------------------|---------------------------------|
|             | E peptides | M peptides | pr peptides | Pooled peptides | E peptides | M peptides | pr peptides | Pooled peptides |
| VRC 319 trial plasmid VRC5288 (Zika virus/JEV chimera) |
| Group 1     | 67 (40 to 114) | 0·031 (0·006 to 0·061); p=0·0362 | 0·01 (-0·011 to 0·03) | 0·012 (-0·006 to 0·029) | 0·051 (-0·012 to 0·114) | 0·013 (-0·005 to 0·032) | 0·017 (-0·003 to 0·037) | 0·023 (-0·004 to 0·051); p=0·0318 | 0·054 (-0·007 to 0·115) |
| Group 2     | 55 (39 to 78) | 0·037 (0·005 to 0·059); p=0·0236 | 0·025 (-0·004 to 0·054) | 0·022 (-0·012 to 0·055) | 0·082 (-0·009 to 0·172) | 0·023 (-0·016 to 0·061) | 0·017 (-0·014 to 0·048) | 0·017 (-0·018 to 0·051) | 0·056 (-0·04 to 0·152) |
| Group 3     | 81 (51 to 127) | 0·019 (0·002 to 0·037) | 0·006 (-0·009 to 0·02) | 0·009 (-0·005 to 0·024) | 0·035 (0·001 to 0·069) | 0·015 (-0·01 to 0·039) | 0·01 (-0·011 to 0·031) | 0·026 (0·014 to 0·038); p=0·0002 | 0·05 (0·005 to 0·096); p=0·0304 |
| Group 4     | 120 (73 to 197) | 0·041 (0·018 to 0·063); p=0·0032 | 0·005 (-0·009 to 0·018) | 0·019 (-0·01 to 0·049) | 0·064 (0·017 to 0·110); p=0·0108 | 0·055; p=0·0046 | 0·007 (-0·004 to 0·021) | 0·024 (-0·001 to 0·049); p=0·0494 | 0·086 (0·039 to 0·134); p=0·0039 |
| VRC 320 trial plasmid VRC5283 (wild-type Zika virus) |
| Group 1     | 48 (28 to 83) | 0·014 (-0·014 to 0·042) | -0·003 (-0·012 to 0·007) | -0·011 (-0·04 to 0·018) | 0·002 (-0·049 to 0·052) | 0·016 (-0·005 to 0·037) | 0·002 (-0·011 to 0·033) | 0·009 (-0·004 to 0·023) | 0·027 (-0·007 to 0·061) |
| Group 2     | 150 (99 to 226) | 0·036 (-0·007 to 0·08) | 0·006 (-0·008 to 0·021) | 0·007 (-0·012 to 0·025) | 0·05 (-0·007 to 0·106); p=0·0353 | 0·008 (-0·043 to 0·06) | 0·009 (-0·002 to 0·015) | 0·018 (-0·007 to 0·043) | 0·016 (-0·053 to 0·085) |
| Group 3     | 304 (215 to 430) | 0·083 (0·029 to 0·126); p=0·0001 | 0·014 (-0·006 to 0·035) | 0·014 (-0·003 to 0·032) | 0·111 (-0·05 to 0·172); p=0·0004 | 0·091 (0·014 to 0·168) | 0·007 (-0·03 to 0·017) | 0·029 (-0·037 to 0·094) | 0·113 (-0·016 to 0·21); p=0·0166 |

Values are displayed as group means; p values are given only for significant differences from baseline. GMT=geometric mean titre. E=envelope protein E. M=small envelope protein M. pr=peptide pr. JEV=Japanese encephalitis virus.

Table 3: Neutralising antibody titres and T-cell responses 4 weeks after final vaccination

Figure 2: Neutralising activity 4 weeks after last vaccination, measured by reporter virus particle assay

In the VRC 319 study, samples were collected in week 12 for groups 1 and 3, week 16 for group 2, and week 24 for group 4. In the VRC 320 study, all samples were collected at week 12. Data are geometric mean titres and SDs derived from two to four independent assays per sample. The dotted line represents the limit of detection of the assay (dilution 1:30). Negative samples were reported as half the limit of detection (dilution 1:15). EC50=dilution of sera required to neutralise half of infection events. N/S=needle and syringe.
Split-dose administration of vaccine with needle and syringe also improved GMT compared with single-dose administration via the same method (appendix). In the two groups receiving VRC5283 by needle and syringe, the antibody levels were higher after splitting the dose (p=0·0015 for group 2). Boosting with the third dose only significantly increased the GMT to greater than that after the second dose in group 1 (p=0·0016). EC80 results are shown in the appendix.

4 weeks after last vaccination with VRC5288 in VRC 319, in group 4, T-cell responses to pooled peptides were significantly increased (CD4 p=0·0108 and CD8 cells p=0·0039) compared with baseline (table 3, figure 4). Group 3 showed increased CD8 (p=0·0304) responses to pooled peptides. The greatest T-cell responses overall were seen 4 weeks after needle-free administration of VRC5283 in VRC 320 (table 3, figure 4). CD8 cell counts in participants who received VRC5283 via needle-free injection had increased total cytokine responses compared with baseline for pooled peptides (p=0·0166) and specifically for E-protein peptides (p=0·0004, appendix). CD4 cell counts from this group were also increased with pooled peptides (p=0·0004), again specifically for E-protein peptides (p=0·0001, appendix). VRC5283 given in split doses via needle and syringe also produced a significant CD4 response to pooled peptides (p=0·0353), but not a significant CD8 response. There were no significant responses to small envelope protein M or pr peptide.

**Discussion**

The emergence of Zika virus challenged the scientific community to address a relatively uncharacterised pathogen posing a substantial threat to international public health. Although symptoms of Zika virus infection are typically mild, infection during pregnancy is associated with a high teratogenic risk. Moreover, sexual transmission by travellers to endemic regions might extend the epidemic to non-endemic regions without requiring a mosquito vector. Rapid development of vaccines has, therefore, been started. The two DNA vaccines we assessed were safe and well tolerated, with most adverse events being mild. Both vaccines were immunogenic, but the greatest effects were seen with VRC5283 given in split doses via needle-free injection in the VRC 320 trial.

Despite the novelty of Zika virus, previous knowledge of flavivirus biology and immunity has pointed towards likely immunogenicity correlates and facilitated development of Zika virus vaccines. For example, neutralising activity is an established correlate of protection for most licensed flavivirus vaccines. In studies of VRC5288 and VRC5283 in non-human primates, neutralising activity correlated with protection against viraemia following
vaccination and Zika virus challenge. Additionally, the role of antibody-mediated protection against Zika virus infection is supported by protection against infection after adoptive transfer of purified IgG from mice vaccinated with a DNA vaccine against Zika virus into CD4 and CD8 T-cell-depleted mice. In addition to humoral immunity, cellular immunity might be relevant, particularly because CD8 T-cell responses have been detected in human beings after flavivirus infections. With this in mind, the DNA vaccine platform has an advantage over protein-based vaccines because it induces antibody and substantial T-cell responses. CD4 T-cell responses are necessary for optimum memory B-cell response, and CD8 T cells are thought to facilitate viral clearance important to fetal protection.

Based on our findings, VRC5283 was more promising than VRC5288 to advance into later stage development because 100% (14 of 14) of participants who received the vaccine by needle-free injection in split doses had detectable antibody responses and had neutralising antibody and T-cell responses of the greatest magnitude. Additionally, CD4 and CD8 T-cell responses were greater with VRC5283 than VRC5288. Since VRC5288 encodes the Japanese encephalitis virus E transmembrane sequence, some cellular immune responses induced by vaccination might have been specific to this virus and not captured by our intracellular cytokine staining assay or might not have been able to respond to Zika virus. The wild-type Zika virus E transmembrane protein in the VRC5283 plasmid might, therefore, elicit cellular immune responses to this region, giving this vaccine a further advantage.

Immune responses differed by vaccine delivery method. Needle-free injectors are known to augment
DNA vaccine response, possibly by increased dispersion of injectogenicity or through tissue damage that increases immunogenicity.25 The GMT after split-dose needle-free delivery of VRC5283 was six times higher than that after single-dose delivery via needle and syringe. The number of injections was also important, as the GMT achieved after VRC5283 was given in split doses via needle and syringe was two to three times greater than those seen with VRC5288 or VRC5283 given in single doses by the same vaccination schedule. The VRC 319 trial used only needle and syringe delivery and, therefore, we could not compare specific variables responsible for different outcomes between the two trials. In non-human primate studies, however, VRC5288 and VRC5283 were both administered by needle-free injection, and VRC5283 prevented viraemia more effectively than VRC5288.22

The antibodies induced by each vaccine are being investigated for qualitative differences that might contribute to their differing protective capacity. Additionally, dose-reduction studies for VRC5283 in non-human primates are being done to define the serological correlate of protection from viraemia. Based on all the available information and the need for a shortened assessment schedule, VRC5283 has been advanced into an international placebo-controlled phase 2 efficacy trial of vaccination at 0, 4, and 8 weeks via needle-free delivery with the Stratis device (NCT03110770). This study aims to assess safety, immunogenicity, and efficacy in populations in regions in South and Central America, the Caribbean, and the USA endemic for Zika virus.

The basis for comparing the serological correlate of protection from viraemia in non-human primates and vaccine immunogenicity in human volunteers is serum neutralising activity measured by the reporter virus particle assay, which yields highly reproducible and sensitive results. This assay measures inhibition of viral entry across a large dynamic range. Moreover, it has been used extensively to define mechanisms of flavivirus neutralisation and has been a reliable endpoint for determining immune correlates in studies of non-human primates26 and human beings.27 The assay correlates with traditional measurements of neutralisation, such as the plaque reduction neutralisation test, that have been used in assessments of previously licensed flavivirus vaccines. The plaque reduction neutralisation test and the microneutralisation assay, however, assess entry and spread of replicating virus in cell culture, and might be unable to detect replication-competent virus that is not neutralised at any concentration. In a phase 1 trial of another Zika virus DNA vaccine, neither the plaque reduction neutralisation test nor the microneutralisation assay predicted whether passively transferred human sera would protect mice against Zika virus challenge.28 Ultimately, efficacy data from field trials will be needed to establish reliable correlates of protection that can be used to refine sufficient doses and schedules for effective immunity.

Much still needs to be done before any vaccine against Zika virus can be deployed. Human trials so far show data from healthy populations suitable for open-label phase 1 trials. Randomised placebo-controlled efficacy trials in volunteers from regions where Zika virus and other flaviviruses are endemic are still needed. An important limitation in the development of any Zika virus vaccine is the lack of established correlates of protection from fetal malformations. Whether established correlates of protection from clinical disease in non-teratogenic flaviviruses will be predictive of prevention of fetal disease with Zika virus is unknown. Whether completely preventing viraemia, reducing peak viraemia, or preventing persistent viraemia in pregnant mothers will provide sufficient fetal protection is also unknown. Similar to the situation for congenital rubella syndrome in the 1960s, sustained epidemiological surveillance of large populations of vaccinated individuals will be needed to confirm effects on congenital infection.

A limitation of this study is the small number of participants. This is, however, typical of phase 1 studies.

Our studies of two ZIKV DNA vaccines, VRC5288 and VRC5283, advance the effort to quickly curb the effects of the Zika epidemic. VRC5283 showed the most robust neutralising antibody and T-cell responses, and has been advanced into an international phase 2 efficacy trial. Several other vaccine approaches are also being pursued. Findings from a human study of another DNA vaccine have been reported,22 and an inactivated vaccine is being assessed in human beings (NCT02963909). Differing vaccines might be designed for distinct target populations, provide various immune response patterns, and varying durability. As the joint efforts continue and knowledge of the immune response to Zika virus deepens, guidance on developing a definitive solution to the epidemic will improve.

Contributors
MRG is the principal investigator of VRC 319. GLC is the principle investigator of VRC 320. CSH, LAH, SE, MAM, NGR, KEL, GEC, and BSG were study investigators. ZH did the statistical analysis. GY, RSR, NB, JLG, JHC, SS, CL, RMS, JRM, BSG, TCP, JEL, and GLC designed the clinical trials. MRG, FM, JGS, LN, CSH, LAH, JLG, SE, MAM, NGR, KEL, and GEC collected data. MRG, KVV, KMM, JHC, RTB, BMF, KB, RSP, DNG, CRD, KAD, JRM, BSG, TCP, JEL, and GLC analysed and interpreted the data. All authors contributed to the writing of the report and approved the final version.

Declaration of interests
We declare no competing interests.

Acknowledgments
We thank the vaccine trial volunteers for their contribution and commitment to vaccine research. We also acknowledge the contributions of our National Institutes of Health (NIH) Clinical Center and National Institute of Allergy and Infectious Diseases (NIAID) colleagues, including the Regulatory Compliance and Human Subjects Protection Branch of the Division of Clinical Research, and the NIAID Institutional Review Board, the EmMes Corporation, and colleagues at the NIAID Vaccine Research Centre (VRC), including members of the Animal Program, Viral Pathogenesis Laboratory, Virology Core, Vaccine Clinical Materials Program, Vaccine Production Program, and Vaccine Immunology Program. We thank Tracy Rockwardt, NIAID VRC, for help in analysing the intracellular cytokine staining assay data and...
Brenda Hartman, NIAID VRC, for assistance with creating the figures. The VRC 319 and VRC 320 study teams at the VRC include

References

1 Fauci AS, Morens DM. Zika virus in the Americas—yet another arbovirus threat. N Engl J Med 2016; 374: 601–04.

2 Dick GW, Kitchen SF, Haddow AJ. Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg 1952; 46: 509–20.

3 Duffy MR, Chen T-H, Hancock WT, et al. Zika virus outbreaks on Yap Island, Federated States of Micronesia. N Engl J Med 2009; 360: 2536–43.

4 Derraik JG, Slaney D. Notes on Zika virus—an emerging pathogen now present in the South Pacific. Aust NZ J Public Health 2015; 39: 5–7.

5 Campos GS, Bandeira AC, Sardi SI. Zika virus outbreak. Bahia, Brazil. Emerg Infect Dis 2015; 21: 1885–86.

6 D’Orentezio E, Matheron S, Yazdanpanah Y, et al. Evidence of sexual transmission of Zika virus. N Engl J Med 2016; 374: 2195–98.

7 Motta IJ, Spencer BR, Cordeiro da Silva SG, et al. Evidence for transmission of Zika virus by platelet transfusion. N Engl J Med 2016; 375: 1101–03.

8 Vasquez AM, Sapiano MR, Basavaraju SV, et al. Zika virus outbreak—region of the Americas, May 15, 2015–December 15, 2016. MMWR Morb Mortal Wkly Rep 2017; 66: 129–14.

9 Heymann DI, Hodgson A, Sall AA, et al. Zika virus and microcephaly: why is this situation a PHEIC? Lancet 2016; 387: 719–21.

10 Krauser F, Riesen M, Reveiz L, et al. Zika virus infection as a cause of congenital brain abnormalities and Guillain–Barré syndrome: systematic review. PLoS Med 2017; 14: e1002203.

11 de Oliveira WK, de Franca GVA, Carmo EH, Duncan BB, de Souza Kuchenbecker R, Schmidt MI. Microcephaly after the 2015 and 2016 Zika virus outbreaks in Brazil: a surveillance-based analysis. Lancet 2017; 390: 861–70.

12 de Oliveira WK, de Franca GVA, Carmo EH, Duncan BB, de Souza Kuchenbecker R, Schmidt MI. Zika virus infection as a cause of congenital brain abnormalities and Guillain–Barré syndrome: systematic review. PLoS Med 2017; 14: e1002203.

13 Martin JE, Louder MK, Holman LA, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a phase 1 clinical trial. Vaccine 2008; 26: 6318–43.

14 Martin JE, Sullivan NJ, Enama ME, et al. A DNA vaccine for Ebola virus is safe and immunogenic in a phase 1 clinical trial. Clin Vaccine Immunol 2006; 13: 1267–77.

15 Beckett CG, Tuddenham D, Burgess T, et al. Evaluation of a prototype dengue-1 DNA vaccine in a phase 1 clinical trial. Vaccine 2011; 29: 960–68.

16 Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007; 196: 1732–40.

17 Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011; 11: 916–24.

18 Sheets RL, Steen J, Manetz TS, et al. Toxicological safety evaluation of DNA plasmid vaccines against HIV-1, Ebola, severe acute respiratory syndrome, or West Nile virus is similar despite differing plasmid backbones or gene-inserts. Toxicol Sci 2006; 91: 620–30.

19 Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194: 1650–60.

20 Allison SL, Studler K, Mandl CW, Kunz C, Heinz FX. Synthesis and secretion of recombinant tick-borne encephalitis virus protein E in soluble and particulate form. J Virol 1995; 69: 5816–20.

21 Davis BS, Chang GJ, Cropp B, et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 2001; 75: 4940–47.

22 Dowd KA, Ko SY, Morabito KM, et al. Rapid development of a DNA vaccine for Zika virus. Science 2016; 354: 237–40.

23 Davis CW, Nguyen HY, Hanna SL, Sánchez MD, Domínguez NE, Pierson TC. West Nile virus discriminated between DC-SIGN and DC-SIGNR for cellular attachment and infection. J Virol 2006; 80: 1290–301.

24 Sarwar UN, Costner P, Enama ME, et al. Safety and immunogenicity of DNA vaccines encoding Ebola virus and Marburg virus wild-type glycoproteins in a phase 1 clinical trial. J Infect Dis 2015; 211: 549–57.

25 Pierson TC, Diamond MS. Vaccine development as a means to control dengue virus pathogenesis: do we know enough? Annu Rev Virol 2014; 1: 375–98.

26 Larocca RA, Abtink P, Peron JP, et al. Vaccine protection against Zika virus from Brazil. Nature 2016; 536: 474–78.

27 Bukowski JS, Kurane I, Lai CJ, Bray M, Falgout B, Ennis FA. Dengue virus-specific cross-reactive CD8+ human cytotoxic T lymphocytes. J Virol 1989; 63: 5086–91.

28 Mongkolsapaya J, Djinrettarissi W, Xu XN, et al. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 2003; 9: 921–27.

29 Sceratron G, Mongkolsapaya J, Yoob S, Roberts C. New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol 2015; 15: 745–59.

30 Liang H, Lee M, Jin X. Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Cell Mol Immunol 2016; 13: 36–46.

31 Graham BS, Enama ME, Nason MC, et al. DNA vaccine delivered by a needle-free injection device improves potency of priming for antibody and CD8+ T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One 2013; 8: e59340.

32 Tebas P, Roberts CC, Muthusami K, et al. Safety and immunogenicity of an anti-Zika virus DNA vaccine—preliminary report. N Engl J Med 2017; published online Oct 4. DOI:10.1056/NEJMoa1708120.